Register entry

Otsuka America Pharmaceutical, Inc.

Registered sites
6
Drug products
62
Live patents
246
Countries
1
Base
Japan
Authorisation

Registered operations

What the FDA has registered these sites to do. This is the regulatory record, not a marketing claim.

Analytical testingActive ingredient (API) manufactureFinished drug manufacturePackaging
Sites

Facilities

6
SiteLocationOperationsFEI
Otsuka Pharmaceutical Co LtdItano-gunJapanAnalytical testing, Finished drug manufacture3003656524
Otsuka Pharmaceutical Co., Ltd.Kanzaki-gunJapanAnalytical testing, Active ingredient (API) manufacture3003808559
Otsuka Pharmaceutical Co LtdMimaJapanAnalytical testing, Finished drug manufacture, Packaging3017406106
Otsuka Pharmaceutical Co LtdNaka-gunJapanAnalytical testing, Finished drug manufacture, Packaging3004810250
Otsuka Pharmaceutical Co LtdTokushimaJapanAnalytical testing, Active ingredient (API) manufacture, Finished drug manufacture3002807834
Otsuka Pharmaceutical Co LtdTokushimaJapanAnalytical testing, Finished drug manufacture3002809299
Exclusivity

Patents

246

Unexpired Orange Book patents where this company is the application holder.

ProductActive ingredientExpiry
ABILIFYARIPIPRAZOLEMar 2027
ABILIFY ASIMTUFIIARIPIPRAZOLEApr 2033
ABILIFY MAINTENA KITARIPIPRAZOLESept 2033
ABILIFY MAINTENA KITARIPIPRAZOLEMar 2034
ABILIFY MAINTENA KITARIPIPRAZOLEApr 2034
ABILIFY MYCITE KITARIPIPRAZOLESept 2026
ABILIFY MYCITE KITARIPIPRAZOLEMar 2027
ABILIFY MYCITE KITARIPIPRAZOLENov 2027
ABILIFY MYCITE KITARIPIPRAZOLEDec 2028
ABILIFY MYCITE KITARIPIPRAZOLEMar 2029
ABILIFY MYCITE KITARIPIPRAZOLEApr 2029
ABILIFY MYCITE KITARIPIPRAZOLEJul 2029
ABILIFY MYCITE KITARIPIPRAZOLEJul 2029
ABILIFY MYCITE KITARIPIPRAZOLEAug 2029
ABILIFY MYCITE KITARIPIPRAZOLESept 2029
ABILIFY MYCITE KITARIPIPRAZOLEDec 2029
ABILIFY MYCITE KITARIPIPRAZOLEDec 2029
ABILIFY MYCITE KITARIPIPRAZOLEMar 2030
ABILIFY MYCITE KITARIPIPRAZOLEApr 2030
ABILIFY MYCITE KITARIPIPRAZOLEJun 2030
ABILIFY MYCITE KITARIPIPRAZOLESept 2030
ABILIFY MYCITE KITARIPIPRAZOLENov 2030
ABILIFY MYCITE KITARIPIPRAZOLENov 2030
ABILIFY MYCITE KITARIPIPRAZOLENov 2030
ABILIFY MYCITE KITARIPIPRAZOLEDec 2030
ABILIFY MYCITE KITARIPIPRAZOLEJul 2031
ABILIFY MYCITE KITARIPIPRAZOLEDec 2031
ABILIFY MYCITE KITARIPIPRAZOLEJun 2032
ABILIFY MYCITE KITARIPIPRAZOLEOct 2033
JYNARQUETOLVAPTANSept 2026
JYNARQUETOLVAPTANApr 2030
REXULTIBREXPIPRAZOLEOct 2026
REXULTIBREXPIPRAZOLEDec 2028
REXULTIBREXPIPRAZOLEJun 2029
REXULTIBREXPIPRAZOLEOct 2032
REXULTIBREXPIPRAZOLEApr 2033
SAMSCATOLVAPTANSept 2026
SAMSCATOLVAPTANApr 2030
Catalogue

Marketed products

62

Showing 62 of 62.

BrandGeneric nameFormCategory
ABILIFYARIPIPRAZOLETABLETNDA
ABILIFYARIPIPRAZOLETABLETNDA
ABILIFYARIPIPRAZOLETABLETNDA
ABILIFYARIPIPRAZOLETABLETNDA
ABILIFYARIPIPRAZOLETABLETNDA
ABILIFYARIPIPRAZOLETABLETNDA
ABILIFY MAINTENAaripiprazoleKITNDA
ABILIFY MAINTENAaripiprazoleKITNDA
ABILIFY MAINTENAaripiprazoleKITNDA
ABILIFY MAINTENAaripiprazoleKITNDA
-ARIPIPRAZOLETABLETDRUG FOR FURTHER PROCESSING
-ARIPIPRAZOLETABLETDRUG FOR FURTHER PROCESSING
-ARIPIPRAZOLETABLETDRUG FOR FURTHER PROCESSING
-ARIPIPRAZOLETABLETDRUG FOR FURTHER PROCESSING
-ARIPIPRAZOLETABLETDRUG FOR FURTHER PROCESSING
-ARIPIPRAZOLETABLETDRUG FOR FURTHER PROCESSING
-ARIPIPRAZOLETABLETDRUG FOR FURTHER PROCESSING
-ARIPIPRAZOLETABLETDRUG FOR FURTHER PROCESSING
-ARIPIPRAZOLETABLETDRUG FOR FURTHER PROCESSING
-ARIPIPRAZOLETABLETDRUG FOR FURTHER PROCESSING
-ARIPIPRAZOLETABLETDRUG FOR FURTHER PROCESSING
-ARIPIPRAZOLETABLETDRUG FOR FURTHER PROCESSING
Abilify AsimtufiiAripiprazoleINJECTION, SUSPENSION, EXTENDED RELEASENDA
Abilify AsimtufiiAripiprazoleINJECTION, SUSPENSION, EXTENDED RELEASENDA
-AripiprazoleINJECTION, SUSPENSION, EXTENDED RELEASEDRUG FOR FURTHER PROCESSING
-AripiprazoleINJECTION, SUSPENSION, EXTENDED RELEASEDRUG FOR FURTHER PROCESSING
-BREXPIPRAZOLETABLETDRUG FOR FURTHER PROCESSING
-BREXPIPRAZOLETABLETDRUG FOR FURTHER PROCESSING
-BREXPIPRAZOLETABLETDRUG FOR FURTHER PROCESSING
-BREXPIPRAZOLETABLETDRUG FOR FURTHER PROCESSING
-BREXPIPRAZOLETABLETDRUG FOR FURTHER PROCESSING
-BREXPIPRAZOLETABLETDRUG FOR FURTHER PROCESSING
-Cedazuridine and DecitabineTABLETDRUG FOR FURTHER PROCESSING
JYNARQUEtolvaptanTABLETNDA
JYNARQUEtolvaptanTABLETNDA
JynarquetolvaptanKITNDA
JynarquetolvaptanKITNDA
JynarquetolvaptanKITNDA
JynarquetolvaptanKITNDA
JynarquetolvaptanKITNDA
Nuedextadextromethorphan hydrobromide and quinidine sulfateCAPSULE, GELATIN COATEDNDA
RexultibrexpiprazoleTABLETNDA
RexultibrexpiprazoleTABLETNDA
RexultibrexpiprazoleTABLETNDA
RexultibrexpiprazoleTABLETNDA
RexultibrexpiprazoleTABLETNDA
RexultibrexpiprazoleTABLETNDA
RexultiBREXPIPRAZOLEKITNDA
RexultiBREXPIPRAZOLEKITNDA
SAMSCAtolvaptanTABLETNDA
SAMSCAtolvaptanTABLETNDA
-TolvaptanTABLETDRUG FOR FURTHER PROCESSING
-TolvaptanTABLETDRUG FOR FURTHER PROCESSING
-TolvaptanTABLETDRUG FOR FURTHER PROCESSING
-TolvaptanTABLETDRUG FOR FURTHER PROCESSING
-TolvaptanTABLETDRUG FOR FURTHER PROCESSING
VOYXACTsibeprenlimabINJECTIONBLA
-aripiprazoleINJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION, EXTENDED RELEASEDRUG FOR FURTHER PROCESSING
-aripiprazoleINJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION, EXTENDED RELEASEDRUG FOR FURTHER PROCESSING
-aripiprazoleINJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION, EXTENDED RELEASEDRUG FOR FURTHER PROCESSING
-aripiprazoleINJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION, EXTENDED RELEASEDRUG FOR FURTHER PROCESSING
-brexpiprazolePOWDERBULK INGREDIENT
Provenance

Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.